references chapter 9 references -...

References Chapter 9

Formulation and Evaluation of Nanoparticles For Better Drug Bioavailability 9-1

REFERENCES

1. Shargel L., Yu A.B., Applied Biopharmaceutics & Pharmacokinetics; 4th edi., New York: McGraw-Hill.,1999.

2. Rowland Malcolm, N. Thomas, Tozer, Clinical Pharmacokinetic

Pharmacodynamics: Concepts and Applications Philadelphia, PA: Lippincott Williams & Wilkins, 4 th edi., 2010.

3. Brahmankar D.M., Jaiswal S.B., Biopharmaceutics and Pharmacokinetic a

treatise, Vallabh prakashan, New Delhi, 2007. 4. Doornbos C.A., Haan P.D., Encyclopedia of pharmaceutical technology;

Swarbrick J, Boylan J C, Marcel Dekker, New York: 1995, 77. 5. Vyas S. P., Khar R.K, Targeted and Controlled Drug Delivery: Novel Carrier

Systems, CBS Publishers, New Delhi, 2002:331- 364. 6. Witztum J.L. Drugs used in the treatment of hyperlipoproteinemias. Goodman

and Gillman’s, The pharmacological basis of therapeutics, Mc Graw Hill, New York, 9 th edi,1996: 891-892.

7. Welling Peter G., Tse Francis L.S., Dighe Shrikant V., Pharmaceutical

Bioequivalence. Drugs and the Pharmaceutical Sciences., New York, NY: Marcel Dekker., 48 th edi.,1991.

8. Chow Shein-Chung, Liu Jen-pei, Design and Analysis of Bioavailability and

Bioequivalence Studies. Biostatistics Series. Boca Raton, FL: CRC Press., 27: 3 edi., 2008.

9. R. Govindarajan, Nagarsenker M.S., Formulation studies and in vivo evaluation

of flurbiprofen-hydroxypropyl beta-cyclodextrin system; Pharm Dev Tech. 2005; 10:105–114.

10. Heaney R.P., Factors Influencing the Measurement of Bioavailability, Taking

Calcium as a Model; J. Nutr. 131,4 Suppl: 2001:1344S-1348S. 11. Srinivasan VS., Bioavailability of Nutrients: A Practical Approach to In Vitro

Demonstration of the Availability of Nutrients in Multivitamin-Mineral Combination Products; J. Nutr. 131,4 Suppl, 2001:1349S-1350S.

12. Hoag SW, Hussain AS., The Impact of Formulation on Bioavailability:

Summary of Workshop Discussion J. Nutr. 131,4 Suppl: 2001. 13. H. Derendorf, H. Mollmann, J. Barth, C. Mollmann, S. Tunn, M. Krieg;

Pharmacokinetics and oral bioavailability of hydrocortisone; J. Clin. Pharmacol., 1991; 31: 473-476.



14. Tortora G.J., principles of anatomy and physiology; 7 th edi. Harper Collins,

1993.

15. Gogate M.S., Erythromycin monograph, in chemical stability of Pharmaceuticals: A hand book for Pharmacists, (K.A. Connors, G. L. Amidon, V.J. Stella, eds), John Wiley and sons, New york, 1986, 2nd edi., 457- 463.

16. S. Yoshioka, Stella V.J., Stability of Drugs and Dosage forms, Chapter 2-

Chemical stability of drug substances, pg.no. 4. 17. Bernkop-Schnurch, Oral Drug Delivery: How do chemical reactions in the

Gastrointestinal tract influence the therapeutic potential of drugs; 2001, 1:117-228.

18. Werle M., A. Samhaber, A. Bernkop-Schnurch, Degradation of teriparatide by

gastro-intestinal proteolytic enzymes; J. Drug Target., 2006,14(3):109 -115. 19. Fuhr U., Drug interactions with grapefruit juice: extent, probable mechanism

and clinical relevance; Drug Safe 1998,18: 251-272. 20. H. Poiger, Ch. Schlatter, Compensation of dietary induced reduction of

tetracycline absorption by simultaneous administration of EDTA, Eur. J. Clin. Pharmacol., 1978, 14(2): 122-131.

21. Manthena V.S., Varma A., Y. Ashokraj, S. Chinmoy, Dey B., P-glycoprotein

inhibitors and their screening: a perspective from bioavailability Enhancement; Pharmacol. Res., 2003, 48:347-359.

22. Waterbeemd H.V., Lennernas H., Artursson P., Drug Bioavailability-Estimation

of solubility, Permeability, Absorption and bioavailability, Chapter 13- The importance of Gut wall metabolism in determining drug bioavailability, Pg. 320.

23. Hunter J., Hirst B.H., The role of P-glycoprotein and related drug efflux

systems in limiting oral absorption; Adv. Drug Deliver. Rev., 1997;25:129–57. 24. Waterbeemd H. V., H.Lennernas, P.Artursson, Drug Bioavailability-Estimation

of solubility Permeability, Absorption and bioavailability, Chapter 13 - The importance of Gut wall metabolism in determining drug bioavailability, Pg. 323.

25. The Merck manual, Online Medical library, Section: Clinical Pharmacology,

Subject: Pharmacokinetics, Topic: Bioavailability. 26. Davis M.E., Brewster M. E., Cyclodextrin-based pharmaceutics: past, present

and future; Nat. Rev. Drug Discov., 2004,3:1023-1035.



27. Gwak H., Choi J., Choi H., Enhanced bioavailability of piroxicam via salt

formation with ethanolamines; Int. J. Pharm., 2005; 297:156-161. 28. Blagden N., Matas M., Gavan P.T., York P., Crystal engineering of active

pharmaceutical ingredients to improve solubility and dissolution rates; Adv. Drug Deliv. Rev., 2007; 59(7): 617-630.

29. Strickley R.G.; Solubilizing Excipients in Oral and Injectable Formulations, Pharm. Res., 2004; 21(2):200-229.

30. G. V. Murali Mohan Babu, C.D.S. Prasad, K.V. Ramana Murthy; Evaluation of

modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine; Int. J. Pharm., 2002, 234:1-17.

31. Water soluble pharmaceutical coating and method for producing coated

pharmaceuticals, United States Patent 5851275. 32. Lopinavir-Ritonavir: A New Protease Inhibitor: Pharmacokinetic,

Pharmacodynamic Profile, Medscape Today, Pharmacotherapy. 2001;21(11). 33. Malingre M.M., Richel D.J., Beijnen J.H., Co-administration of Cyclosporine

strongly enhances the oral bioavailability of docetaxel, J. Clin. Oncol., 2001; 19(4):1160-1166.

34. Baboota S., Shah M.S., Javed A., Ahuja A., Effect of poloxamer 188 on

lymphatic uptake of carvedilol loaded solid lipid nanoparticles for bioavailability enhancement; J. Drug Target., 2009;17(3):249-256.

35. D. Emanuele, R. Jevprasesphant, J. Penny, D. Attwood; The use of a

dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability; J. Control. Rel., 2004;95(3): 447- 453.

36. Ke W., Zhao Y., Huang R., Jiang C., Pei Y., Enhanced oral bioavailability of

doxorubicin in a dendrimer drug delivery system; J. Pharm. Sci., 2008;97(6): 2208-2216.

37. Khoo S.M., Humberstone A.J., Porter C. J. H., Edwards G.A., Formulation

design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine; Int. J. Pharm., 1998; 167(1-2):155-164.

38. Kasim NA, Whitehouse M, Ramachandran Ch, et al.; Molecular Properties of

WHO Essential Drugs and Provisional Biopharmaceutical Classification; Mol Pharm 2004; 1: 85 -96.

39. Lindenberg M, Kopp S, Dressman JB.; Classification of orally administered

drugs on the World Health Organization Model list of Essential Medicines



according to the biopharmaceutics classification system; Eur J Pharm Biopharm, 2004; 58: 265-278.

40. Amidon GL, Lennernas H, Shah VP, Crison JR., A theoretical basis for a

biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability; Pharm Res, 1995; 12: 413-420.

41. Sachan NK., Bhattacharya A., S Pushkar. and Mishra A.; Biopharmaceutical

classification system: A strategic tool for oral drug delivery technology; Asian J.Pharm., 2009, 3: 76-81.

42. Amidon GL., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability; Pharm. Res,. 1995; 12: 425- 434.

43. Yu L.X., Amidon G.L., Polli J.L., Zhao H., Mehta M.U.; Biopharmaceutical

classification system: The scientific basis for biowaiver extensions; Pharm. Res., 2002; 19: 921-925.

44. Lipinski C.; Poor aqueous solubility an industry wide problem in drug delivery.

Am Pharm Rev., 2002; 5: 82-85. 45. Krishna A.K. and Flanagan D.R.; Micellar solubilization of a new antimalarial

drug; J. Pharm. Sci., 1989; 78: 574-577. 46. Mallick S., Pattnaik S., and Swain K., Current Perspectives of Solubilization: Potential for Improved Bioavailability; Drug Dev. Ind. Pharm., 2007; 33: 865- 873. 47. J. Hu, K.P. Johnson, Williams R.O., Nanoparticle engineering processes for

enhancing the dissolution rates of poorly water soluble drugs, Drug Dev. Ind. Pharm., 2004;30(3):233- 245.

48. Couvreur P, Vauthier C.; Nanotechnology: intelligent design to treat complex

disease; Pharm Res 2006; 23(7): 284-288. 49. Mohanraj V.J., Chen Y.; Nanoparticles - a Review, Trop J Pharm Res., 2006;

5(1): 561-573. 50. Majeti N.V., Kumar R.; Nano and microparticles as controlled drug delivery

devices; J. Pharm Sci., 2000; 3(2): 234-258. 51. N. Arunkumar, M. Deecaraman, C Rani, Nanosuspension technology and its

applications in drug delivery; Asian Journal of Pharmaceutics, 2009; 3:168-173.



52. Soppimath K.; Aminabhavi T.; Kulkarni A., Rudzinski W.; Biodegradable polymeric nanoparticles as drug delivery devices; J. Control. Rel., 2001;70:1- 20.

53. Alonso M.J.; Nanoparticulate drug carrier technology, in microparticulate systems for the delivery of proteins and vaccines, Cohen S. and Bernstein H. (Eds.) Marvel Dekker, New York, 1996; 203-242.

54. Lamprecht A., Ubrich N., Perez M. H.; Biodegradable monodispersed

nanoparticles prepared by pressure homogenization-emulsification; Int. J. Pharm., 1999;184:97-105.

55. Bodmeier R., McGinity J. W.; Solvent selection in the preparation of poly (D,L-

lactide) microspheres prepared by the solvent evaporation method; Int. J. Pharma., 1988; 43: 179-186.

56. Fessi H., Dubrasquet M., Devissaguet J.H, et.al.; Pharmacokinetic evaluation of indomethacin nanocapsules; Drug Des. Del.,1989; 4: 295-302.

57. Kreuter J.; Nanoparticles in Colloidal drug delivery systems, Kreuter (Eds.)

Marvel Dekker, New York, 1994; 219-342. 58. Allemann E., Gurny R., Doelker E.; Drug-loaded nanoparticles preparation

methods and drug targeting issues; Eur. J. Pharm. Biopharm., 1993; 9: 173-191.

59. Allemann E., Doelker E. and Gurny R.; New approach for the preparation of

nanoparticles by an emulsification-diffusion method; Eur. J. Pharm. Biopharm.,1995; 40:14-18.

60. J.M. Barichello, M. Morishita, K. Takayama, T. Nagai; Encapsulation of

hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method; Drug Dev Ind Pharm., 1999; 25(4):471- 476.

61. Chothy M.F., Danenberg J. et al., Lipophillic drug loaded nanospheres

prepared by Nanoprecipitation technique: effect of formulation variables on size, drug delivery and release kinetics; J. Control. Release, 2002; 83: 389-400.

62. Allemann E., Gurny R. and Doelker E., In vitro extended-release properties of

drug-loaded poly(D,L-lactic acid) nanoparticles produced by a salting-out procedure, Pharm. Res., 1993;10:1732-1737.

63. Leroux J.C, Allemann E., De Jaeghere F., Biodegradable nanoparticles from

sustained release formulations to improved site specific drug delivery; J.Control. Rel., 1996; 39:339-350.



64. Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E, Influence of stabilizing agents and preparative variables on the formation of poly (D, L-lactic acid) nanoparticles by an emulsification-diffusion technique; Int J Pharm, 1996;143:133-141.

65. Calvo P., Remunan-Lopez C., Vila-Jato J. L. and Alonso M.J., J. Appl. Polym.

Sci., 1997; 63: 125-132. 66. Patel Paresh N., Patel L. J. and Patel J. K., Development and testing of novel

temoxifen citrate loaded chitosan nanoparticles using ionic gelation method; Der Pharmacia Sinica, 2011; 2 (4):17-25.

67. Kafshgari Morteza Hasanzadeh, Khorram Mohammad, Khodadoost Mobina,

and Khavari Sahar, Reinforcement of Chitosan Nanoparticles Obtained by an Ionic Cross-linking Process; Iranian Polymer Journal, 2011;20(5): 445-456.

68. Shu X.Z., Zhu K.J.; A novel approach to prepare tripolyphosphate /chitosan

complex beads for controlled drug delivery; Int. J. Pharm., 2000; 201:51-58. 69. Mi FL, Shyu S., Lee S., Wong S.T., Kinetic study of chitosan-tripolyphosphate

complex and acid resistive properties for the chitosan-tripolyphosphate gel beads prepared by in-liquid curing method.; J. Polym. Sci. Polym. Phys., 1999; 37:1551-1564.

70. Lim L.Y., Wan L.S., Thai P.Y., Chitosan microspheres prepared by

emulsification and ionotropic gelation; Drug Dev. Ind. Pharm., 1997;23: 981-985.

71. S. Shiraishi, T. Imai, M. Otagiri, Controlled release of indomethacin by

chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation; J. Control. Release,1993;25:217-225.

72. Bodmeier R.H., Parmar K.H., preparation and evaluation of drug containing

chitosan beads; Drug. Dev. Ind. Pharm. 15:1475-1494. 73. Krishna Sailaja , A. Amareshwar; Preparation of chitosan coated nanoparticles

by emulsion polymerization technique; Asian Journal of Pharmaceutical and Clinical Research, 2011; 4(1): 73-74.

74. Coester C., Langer K., Kreuter J.; Gelatin nanoparticles by two step desolvation

a new preparation method, surface modifications and cell uptake; J. Microencapsulation, 2000;17:187-193.

75. Hwang S.J, Jun S.W., Kim M.S, Kim J.S, Park H.J., Lee S., Woo J.S.; Preparation

and characterization of simvastatin/hydroxypropyl-b-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process; European Journal of Pharmaceutics and Biopharmaceutics, 2007; 66: 413- 421.



76. Turk M., Hils P., Helfgen B., Schaber K., Martin H., Wahl M.A.; Micronization of

pharmaceutical substances by the Rapid Expansion of Supercritical Solutions (RESS): A promising method to improve bioavailability of poorly soluble pharmaceutical agents; J Supercrit Fluids, 2002; 22:75-84.

77. Mehta Ashish K., Yadav K.S., Sawant Krutika K., Nimodipine Loaded PLGA

Nanoparticles: Formulation Optimization Using Factorial Design, Characterization and In Vitro Evaluation; Current Drug Delivery, 2007; 4:185-193.

78. Santander Ortega M.J., Jodar Reyes A.B., Csaba N., et al.; Colloidal stability of

Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms; J Colloid Interface Sci., 2006;302:522-529.

79. Gliding D.K., Reed A.M.; Biodegradable polymers for used in surgery,(poly

glycolic acid/ polylactic acid) homo and copolymers, Polymer; 1979, 20:1459-1464.

80. Santander Ortega M.J., Jodar-Reyes A.B., Csabac N., et al., Colloidal stability of

Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms; Journal of Colloid and Interface Science, 2006; 302:522-529.

81. Koa J.A., Park H.J., Hwang S.J., Park J.B., Lee J.S., Preparation and characterization of chitosan microparticles intended for controlled drug delivery; International Journal of Pharmaceutics, 2002; 249:165-174.

82. Joseph Nisha Mary and Sharma Pramod Kumar, Cross-linked nanoparticles of

cytarabine: encapsulation, storage and in-vitro release; African Journal of Pharmacy and Pharmacology, 2007;(1):10-13.

83. Langer K., Zimmer A., Kreuter J., etal., Characterisation of

polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans; Int. J. Pharm., 1994; 110:21-27.

84. Magenheim B. and Benita S., Nanoparticle characterization: a comprehensive

physicochemical approach; Pharma Sciences, 1991;1:221-241. 85. Krause K. P. and Muller R. H.; Production and characterization of highly

concentrated nanosuspensions by high pressure homogenization; Int. J. Pharm., 2001; 214:21-24.

86. Delgado V., Gonzalez-Caballero F., Hunter R. J., Koopal L. K., Lyklema J.,

Measurement and Interpretation of Electrokinetic Phenomena (IUPAC Technical Report). Pure Appl. Chem. 2005; 77 (10): 1753-1850.



87. Barratt G., Characterization of colloidal drug carrier systems with zeta potential measurements. Pharm Technol Eur, 1999;1:25-32.

88. Rawle A., (Malvern Instruments Limited, Enigma business Park, Grove wood

Road, Malvern, Worcestershire, UK). Basic principles of particle size analysis. Technical paper. Malvern Instruments; Report No.: MRK034.

89. Lipid research Clinical Program, The Lipid Research Clinics Coronary Primary

Prevention Trial Results: reduction in incidence of Coronary heart disease, JAMA, 1984: 251-351.

90. Godkar Praful B., Godkar Darshan P., Medical laboratory technology, Bhalani

publishing house, Mumbai, 2006; 2: 352-380. 91. Framer J.A., Gotto A.M., Dyslipidemia and other risk factors for coronary

artery disease, cardiovascular medicine, W.B. Saunders, 1997:5. 92. Gaw A., Packard C.J., Comparative chemistry, pharmacology and mechanism

of action of the statins, J. Statins. The HMG CoA reductase inhibitors in perspective, Martin Dunitz, London, 2000: 49-61.

93. Corsini A., Maggi F.M., Catapano A.L.; Pharmacology of competitive inhibitors

of HMG-CoA reductase., Pharmacol. Res. 1995; 31: 9-27. 94. Lennernas H., Fager G., Pharmacodynamics and pharmacokinetics of the

HMG-CoA reductase inhibitors., Clin. Pharmacokinet.,1997; 32:403-425.

95. Shepherd J., Hunninghake D.B., Barter P., McKenney J.M., Hutchinson H.G., Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of Rosuvastatin with Atorvastatin, Pravastatin, and Simvastatin for achieving lipid-lowering goals; Am J Cardiol 2003; 91(Suppl 1):11C-19C.

96. Ramani Vinod, Chuhan Sachin, Joshi Jibin, Ghelani Tejas, Deshmukh, Gajanan

formulation and evaluation of nanoparticles of hmg -coa reductase inhibitor; International Journal of Pharmaceutical Sciences, 2011;1(1):1135-1151.

97. Patil Mukesh S., Bavaskar Kedar R. et al., Preparation and optimization of

simvastatin nanoparticle for solubility enhancement and in- vivo study; International journal of Pharma research and development, 2011; 2(12):219-226.

98. Zhanga Z., Bua H., Gaoa Z., Huanga Y., Gaoa F., Li Y., The characteristics and

mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats; Int J Pharm 2010;394:147-53.



99. Pandya Vikram M., Patel Jayvadan K and Patel Dhaval J., Formulation, Optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique; Der Pharmacia Lettre, 2011, 3(2): 129-140.

100. V. Devi Kusum, Bhosale U.V., formulation and optimization of polymeric nano

drug delivery system of acyclovir using 3² full factorial design; International Journal of PharmTech Research, 2009; 1(3), 644-653.

101. Patil Pradeep, Patil Vandana, Paradkar Anant, Formulation of a self-

emulsifying system for oral delivery of simvastatin: In vitro and in vivo evaluation; Acta Pharm., 2007; 57: 111–122.

102. Dustgania Amir, Farahania Ebrahim Vasheghani, Imanib Mohammad,

Preparation of Chitosan Nanoparticles Loaded by Dexamethasone Sodium Phosphate; Journal of Pharmaceutical Sciences, 2008; 4(2):111-114.

103. Chen Weiyang, Cross-linked chitosan in mini-tablets for controlled drug

release by, school of phamarcy, faculty of health sciences tshwane university of technology, (M. Tech) dissertation, 2005.

104. Xiaomei Wang, Na Chi, Xing Tang; Preparation of estradiol chitosan

nanoparticles for improving nasal absorption and brain targeting; European Journal of Pharmaceutics and Biopharmaceutics, 2008;70:735–740.

105. Bhumkar Devika R., Pokharkar V.B.; Studies on effect of pH on cross-linking of

chitosan with sodium tripolyphosphate; AAPS Pharmasci Tech: 2006; 7(2): 50. 106. Saha Partha, Goyal Amit K. and Goutam Rath, Formulation and Evaluation of

Chitosan-Based Ampicillin Trihydrate Nanoparticles; Tropical Journal of Pharmaceutical Research, 2010; 9 (5): 483-488.

107. Nanjwade Basavaraj K., Derkar Ganesh K., Bechra Hiren M., Nanjwade Veerendra K. and Manvi F.V., Design and Characterization of Nanocrystals of Lovastatin for Solubility and Dissolution Enhancement; J Nanomedic Nanotechnol 2011, 2:2.

108. Zlatko Pflaum, Domzale, Mateja Salobir et al, Boston, USA, Solid

pharmaceutical formulation containing lovastatin and simvastatin and it’s preparation.:US patent application no.US/2004/0138295A1 dated 15 July 2004.

109. Company literature on ZOCOR® (Simvastatin) Tablets. NJ, USA: Merck and

Co., Inc; 2004:1-12.



110. Astete C. E. and Sabliov C. M.; Synthesis and characterization of PLGA nanoparticles; Journal of Biomaterials Science - Polymer Edition, 2006;17(3): 247–289.

111. Agnihotri S.A., Mallikarjuna N.N., Aminabhavi T.M., Recent advances on

chitosan based micro and nanoparticles drug delivery; Journal of controlled release; 2004;100: 5-28.

112. BASF Corporation, 3000 Continental Drive-North Mount Olive, New Jersey. 113. Gan et al., Modulation of surface charge, particle size and morphological

properties of chitosan-TPP nanoparticles intended for gene delivery; Colloids and Surfaces B: Biointerfaces, 2005; 44:65-73.

114. Wand Asgharnejad M, Second Derivative UV Spectrometric determination of

simvastatin in its tablet dosage form; Journal of Pharmaceutical and Biomedical Analysis 2000; 21: 1243-1248.

115. Nirogi R., Mudigonda K., Kandikere V., Chromatography-mass spectrometry

methods for the quantitation of statins in biological samples; J Pharm Biomed Anal, 2007;44:379-387.

116. Shyu S.S., Kuan C.Y., Lee S.T., Lu K.T., Jang S.F., Chitosan polyelectrolyte

complexation for the preparation of gel beads and controlled release of anticancer drug. Enzymatic hydrolysis of polymer; J. Appl. Polym. Sci., 1990; 74:1868-1879.

117. Panyam J., Dali M.M., Sahoo S.K., et al.; Polymer degradation and in vitro

release of model protein from poly (D, L-lactide-co-glycolide) nano- and microparticles; J Control Rel., 2003;92:173-187.

118. Mukdavan Prakobvaitayakit and Ubonthip Nimmannit; Optimization of

Polylactic-Co-Glycolic Acid Nanoparticles Containing Itra-conazole Using 23 Factorial Design; AAPS PharmSciTech 2003;4(4):1-9.

119. Stetsko G., Statistical experimental design and its application to

pharmaceutical development problems; Drug Dev Ind. Pharm., 1986; 12:1109-1123.

120. Souto E. B., Muller R. H., Nanoparticles for Pharmaceutical Applications; Domb A, Tabata Y, Kumar R, Eds.; American Scientific Publishers, 2006:103.

121. Hecq J., Deleers M, Fanara D., Vrandex H., Amighi K., Preparation and

characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine; International Journal of Pharmaceutics, 2005; 299: 167-177.



122. Kocbek P, Baumgartner S., Kristi J., Preparation and evaluation of

nanosuspensions for enhancing dissolution of poorly soluble drugs; International Journal of Pharmaceutics, 2006; 312(1-2):179-186.

123. Lourenco C, Teixeira M, Simees S, Gaspar R., Steric stabilization of

nanoparticles: Size and surface properties; Int J Pharm 1996;138:1-12. 124. Lewis G A, Mathieu D, Phan-Tan-Luu R, Pharmaceutical experimental design:

Drugs and Pharmaceutical Sciences; Marcel Dekker,; New York: 1999, 1st edi.; 235.

125. Wedad Ashour Fourjani, In vitro anticancer properties of linamarin

controlled release from biodegradable poly-lactic co-glycolic acid nanoparticle, Universiti Putra Malaysia, 2005.

126. Yuichi T., Atsutoshi I., Hiiroko S., Toshio O., Keiji Y., Characterization and

quantitation of Clarithromycin polymorphs by powder X-Ray diffractometry and solid state NMR spectroscopy; Chemical & Pharmaceutical Bulletin 2002; 50:1128-1130.

127. Kristi J., Baumgartner S., Planinsek O., Dolenc A.; Advantages of celecoxib

nanosuspension formulation and transformation into tablets; International Journal of Pharmaceutics, 2009;376(1-2): 204-212.

128. S. Magdassi and G.K Margulis; Formation of simvastatin nanoparticles from

microemulsion; Nanotechnology, Biology and Medicine in Nanomedicine, 2009;5: 274-281.

129. Dubey Arunkumar, Ahalya Devi, Kutty Gopalan and Pathiyil Ravi,

Hypolipidemic Activity of Ginkgo biloba Extract, EGb 761 in Hypercholesterolemic Wistar Rats; Iranian Journal of Pharmacology & Therapeutics, 2005; 4:9-12.

130. Cheng H., Sutton S. C., Pipkin J. D., Zentner G. M., Rogers J. D., Evaluation of

sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors in dogs and humans; Pharm.Res. 1993;10:1683-1687.

131. Ambike A., Mahadik K. R. and Paradkar A.R.; Spray dried amorphous solid

dispersions of simvastatin; a low Tg drug: In vitro and in vivo evaluations; Pharm. Res., 2005; 22:990-998.

132. Guidance for industry, estimating the maximum safe starting dose in initial

clinical trials for therapeutics in adult healthy volunteers US department of health and human services, FDA centre for drug evaluation and research (CDER), July 2005, Pharmacology and Toxicology.



133. Nirogi Ramkrishna, Mudigonda Koteshwara, Kandikere Vishwottam,

Chromatography- mass spectrophotometry methods for the quantitation of statin in biological samples; Journal of Pharmaceutical and Biomedical Analysis, 2007, 44: 379- 387.

134. Madan P.L.; Biopharmaceutics and Pharmacokinetic, Jaypee publication, New

Delhi, 2000;1: 233-282. 135. Bhasir Sajid, Jamshaid Mohammad, Ahmed Bhasir, Pharmacokinetic of

ciprofloxacin in Normal rabbits and changes observed in induced dehydrate state; Pak. J. Pharm. Sci. 2008; 21(3):225- 229.

136. Khoo S. M., Humberstone A.J., Porter C.J. H, Edwards G.A., Charman W. N.,

Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine, Int. J. Pharm, 1998;167: 155-164.

137. International Conference on the Harmonization of Technical Requirements

for the Registration of Pharmaceuticals for Human Use (ICH) Q2B; Validation of Analytical Procedures: Methodology, November 6, 1996; London, UK.

138. ICH QIA (R2), Stability testing guidelines: Stability testing of new drug

substances and products, The European agency for the evaluation of medicinal products. 2003, CPMP/ICH/273/99:4-20.

139. Yoshioka S., Stella V. J., Stability of Drugs and Dosage forms, Chapter 2-

Chemical stability of drug substances, pg.no. 4. 140. Nti-Gyabaah J, Chmielowski R, Chan V, Chiw Y.C.; Solubility of lovastatin in a

family of six alcohols: Ethanol, 1-propanol, 1-butanol, 1-pentanol, 1-hexanol and 1-ioctanol. Int J Pharm., 2008;359:111-117.

141. Brenner G.S., Ellison D.K. and Kaufman M.J.; Lovastatin. In: Brittain HG (ed.)

Analytical Profiles of Drug Substances. Academic Press Inc., California, 2005: 277-305.

142. R. Sureshkumar, Subhashish Debnath, GNK Ganesh; Chitosan nanoparticles

by Ionotropic Gelation containing L- Arginine; Research J. Pharm. And Tech. 2009;2(1): 80-85.

143. Calvo P., Remunan Lopez, C. Vila Jato J.L. and Alonso M. J., J. Appl. Polym.

Sci., 1997;63:125-132. 144. Shiraishi S., Imai T., Otagiri M.; Controlled release of Indomethacin by

chitosan-polyelectrolyte complex: optimization and in vivo/in vitro evaluation; J. Control. Release, 1993;25:217-225.



145. Pan H.Y., DeVault A.R., Wang Iverson D., Ivashkiv E., Swanson B.N., Comparative pharmacokinetics and pharmacodynamics of Pravastatin and Lovastatin; J. Clin. Pharmacol., 1990;30:1128-1135.

146. G. Suresh, K. Manjunath, V. Venkateswarlu, V. Satyanarayana, Preparation,

Characterization, and In Vitro and In Vivo Evaluation of Lovastatin Solid Lipid Nanoparticles; AAPS PharmSciTech 2007; 8 (1) Article 24, E1-E9.

references chapter 9 references -...

Documents